CVRx, Inc. (NASDAQ: CVRX)

$5.75 ▲ +0.53 (+10.15%)
As of May 14, 2026 03:59 PM
Sector: Healthcare Industry: Medical Devices CIK: 0001235912
Market Cap 137.44 Mn
P/E -2.59
P/S 2.33
Div. Yield 0.00
ROIC (Qtr) 0.00
Total Debt (Qtr) 58.49 Mn
Revenue Growth (1y) (Qtr) 19.61
Add ratio to table...

About

CVRx is a commercial stage medical device company focused on developing manufacturing and commercializing innovative neuromodulation solutions that use procedures with only small incisions for patients with cardiovascular disease. The company’s primary product is the Barostim system which delivers electrical pulses to baroreceptors in the carotid artery to treat heart failure with reduced ejection fraction. CVRx generates revenue primarily from the sale of the Barostim implantable pulse generator and stimulation lead to hospitals and health care...

Read more

Investment thesis

Bull case

  • The implementation of the Category I CPT code at the beginning of 2026 marks a structural shift that removes prior‑authorization friction, directly translating into higher reimbursement predictability and smoother patient access. The company’s sales organization, now operating with 53 territories and 252 active implanting centers, has demonstrated a scalable model whereby top‑20 % centers already achieve 19 implants annually. This evidence suggests a rapid “fly‑wheel” effect that can sustain high implant rates as the sales force matures, reinforcing long‑term revenue momentum.
  • The launch of the BENEFIT HF trial represents a hidden catalyst that is unlikely to impact 2026 revenue materially but will generate significant real‑world evidence and market credibility. The trial’s inclusion of patients with EF up to 50% and NT‑proBNP up to 5,000 expands the therapeutic indication, potentially tripling the addressable market from $10.5 bn to $30 bn. The trial’s 2,500‑patient enrollment will produce a stream of Medicare‑covered device revenue of $20‑30 m over five to seven years, creating a predictable cash flow that strengthens the company’s long‑term balance sheet.
  • Gross margin expansion to 86 % in Q4, up from 83 % a year earlier, underscores a manufacturing efficiency trajectory that can be further leveraged as unit volume scales. The company’s ability to increase average selling price while simultaneously reducing cost per unit demonstrates operational discipline that, if sustained, will offset rising SG&A expenses and move the company toward profitability.
  • The company’s European expansion, albeit modest, indicates a strategic foothold in a new geographical market. With European revenue increasing 10 % to $1.1 m, and active centers growing to 49, the organization has proven its commercial model can be replicated outside the United States. Coupled with potential new reimbursement codes in the EU, this incremental diversification mitigates U.S.‑centric risk and provides a platform for future growth.
  • The debt‑facility amendment extends maturity to 2031 and unlocks up to $40 m contingent on revenue milestones, effectively offering a non‑dilutive capital buffer that can be deployed for further sales expansion or to fund the BENEFIT HF trial without immediate equity dilution. The company’s robust $75.7 m cash position at year‑end, combined with two years of cash runway, provides financial resilience that can absorb seasonal revenue dips and operational scaling costs.
Read more

Bear case

  • The persistent net loss of $11.9 m in 2025, with SG&A expenses growing 9 % to $22 m, signals that the company is still burning cash at a rate that could outpace revenue acceleration if sales productivity stalls. The current burn of $40.8 m in operating and investing activities leaves only a two‑year cash runway, a buffer that could quickly erode if the company fails to meet its aggressive sales targets or encounters unforeseen regulatory delays.
  • The company’s quarterly active implanting center growth has stalled, rising only 2 centers from Q3 to Q4 and reflecting account closures that offset new additions. Management explicitly highlighted that sequential growth in active centers is minimal and that seasonal dips are expected, casting doubt on the sustainability of the current adoption momentum. If the growth in implanting centers does not materialize, the company's revenue base may remain fragile.
  • Although the BENEFIT HF trial expands the potential market, its success is contingent on enrolling 2,500 patients, a large undertaking for a company with limited commercial footprint. The trial’s clinical endpoints are mortality and hospitalization, outcomes that may require several years of data to validate. Until positive results are published, the company’s ability to justify a tripled addressable market remains speculative, exposing investors to over‑optimistic valuation multiples.
  • The Category I CPT code, while removing prior‑authorization barriers, has yet to fully permeate payer systems, and the company reports a still‑significant transition period. Payers that historically denied 100 % of prior authorizations are now approving at a higher rate, but the company notes that full adoption will take several quarters. Until reimbursement becomes fully predictable, cash flow timing could remain uncertain, undermining the expected revenue acceleration.
  • The company’s European market penetration remains modest, with only 49 active centers and $1.1 m in revenue. Without significant investment to build a comparable sales force and navigate disparate reimbursement landscapes, CVRx risks becoming overly dependent on the U.S. market, which could expose it to regulatory, policy, or demographic headwinds that are beyond the company’s control.
Read more

Geographical Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 145.93 Bn 23.33 3.23 34.05 Bn
2 SYK Stryker Corp 115.71 Bn 34.62 4.58 14.72 Bn
3 MDT Medtronic plc 97.69 Bn 21.17 2.75 28.07 Bn
4 BSX Boston Scientific Corp 78.71 Bn 22.00 3.82 11.03 Bn
5 EW Edwards Lifesciences Corp 47.63 Bn 44.75 7.85 0.60 Bn
6 PHG Koninklijke Philips Nv 29.38 Bn 13,009.40 1.46 8.07 Bn
7 DXCM Dexcom Inc 22.72 Bn 24.58 4.72 -
8 STE STERIS plc 20.71 Bn 29.06 3.55 1.90 Bn